文献速递神经胸部MR

肺腺癌脑转移GAP43的影像基因组学评估

Non-invasive radiogenomic assessment of growth-associated protein 43 in lung adenocarcinoma brain metastases.
PubMed 文献 · Eur J Radiol · 2026-08-22

该研究回顾性纳入308例手术切除的肺腺癌脑转移患者,其中56例有RNA测序和增强T1WI用于构建预测GAP43表达的影像组学模型,另252例用于预后验证。模型预测GAP43表达的AUC为0.825,影像组学评分较高者总生存期更差。

要点

  • 增强T1WI影像组学评分较高提示肺腺癌脑转移患者总生存期较短
  • GAP43高表达与总生存期差相关,可作为脑转移不良预后标志物
  • 基于影像组学评分的列线图可用于个体化短期生存分层

核心结论

  • GAP43是肺腺癌脑转移的不良预后生物标志物
  • 基于CE-T1WI的影像基因组学模型可较准确预测GAP43表达
  • 影像组学评分较高与肺腺癌脑转移患者总生存期较差独立相关

研究设计与样本

  • 回顾性研究,纳入2012-2021年308例手术切除的肺腺癌脑转移患者
  • 56例有配对RNA测序和增强T1WI的患者用于构建影像组学模型预测GAP43表达
  • 另252例独立队列用于影像组学评分的探索性预后评估
  • 使用PyRadiomics提取1130个影像组学特征,经过ICC可重复性评估、t检验、冗余过滤和LASSO筛选
  • 构建优化支持向量机模型预测GAP43表达并生成影像组学评分

关键影像表现/征象

  • GAP43高表达与活化肥大细胞(R=0.53)和嗜酸性粒细胞(R=0.34)正相关
  • 影像组学评分较高的脑转移灶对应较短总生存期

诊断标准与关键数值

  • GAP43独立与较差总生存期相关(P=0.026)
  • 影像基因组学模型在重复嵌套交叉验证中预测GAP43表达的AUC为0.825(95%CI,0.791-0.858)
  • 影像组学评分较高独立与较差总生存期相关(P<0.001)
  • 基于影像组学评分的列线图3、6、12个月总生存期时间依赖性AUC分别为0.661、0.666和0.631

临床应用与阅片要点

  • 在日常阅片中可关注肺腺癌脑转移灶的增强T1WI影像组学特征,用于判断GAP43表达水平和短期生存风险
  • 影像组学评分较高的脑转移患者需更密切随访或考虑更积极治疗
  • 基于影像组学评分的列线图可用于3至12个月短期生存分层

局限性

  • 回顾性研究设计
  • 影像组学模型构建队列样本量为56例,较小
  • 建模队列与预后验证队列来自同一时间段,存在选择偏倚可能

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: To evaluate the prognostic role of growth-associated protein 43 (GAP43) in lung adenocarcinoma (LUAD) brain metastases and develop a non-invasive radiogenomic model combining MRI radiomics with transcriptomics for GAP43 prediction and survival estimation.

METHODS: This retrospective study included 308 patients with surgically resected LUAD brain metastases (2012-2021). Fifty-six patients with paired RNA sequencing and contrast-enhanced T1-weighted MRI (CE-T1WI) were used to build the radiomics model predicting GAP43 expression. An additional independent cohort of 252 patients was included for exploratory prognostic evaluation of the imaging-derived radiomics score (RS). Radiomic features (n = 1,130) were extracted using PyRadiomics and underwent sequential feature selection, including inter-observer reproducibility assessment using intraclass correlation coefficients (ICCs), univariate t-tests, correlation-based redundancy filtering, and least absolute shrinkage and selection operator (LASSO)-based feature selection. An optimized support vector machine (SVM) model was subsequently developed to predict GAP43 expression and generate the RS. Survival was analyzed via Kaplan-Meier and Cox regression.

RESULTS: A total of 56 patients were enrolled in the radiogenomics cohort. GAP43 was significantly independently associated with poorer overall survival (OS; P = 0.026). High GAP43 expression correlated positively with activated mast cells (R = 0.53), eosinophils (R = 0.34). The radiogenomic model showed favorable performance for predicting GAP43 expression in repeated nested cross-validation, with an AUC of 0.825 (95% CI, 0.791-0.858). In an independent prognostic cohort of 252 patients, a higher imaging-derived radiomics score (RS) was independently associated with poorer OS (P < 0.001). The RS-based nomogram showed acceptable prognostic performance, with time-dependent AUCs of 0.661, 0.666, and 0.631 for 3-, 6-, and 12-month OS, respectively.

CONCLUSIONS: GAP43 is an adverse prognostic biomarker in LUAD brain metastases. A CE-T1WI radiogenomic model accurately predicts GAP43 expression, facilitating individualized short-term survival stratification.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Sun, Liu, Jiang, et al. Non-invasive radiogenomic assessment of growth-associated protein 43 in lung adenocarcinoma brain metastases. Eur J Radiol. 2026. PMID: 42648196. doi:10.1016/j.ejrad.2026.113181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。